

HUNTINGTON DISEASE is a

**fatal, hereditary
brain disorder**



EVERY CHILD born to a parent with HD

**has a 50% chance of
sharing the same fate**



Huntington Disease

Learn More

**Right now, every dollar
makes a difference.**

**To donate, visit
cureHD.ca**

or call

1.800.998.7398




Huntington Society of Canada
151 Frederick Street, Suite 400, Kitchener, ON N2H 2M2

1-800-998-7398

huntingtonsociety.ca info@huntingtonsociety.ca

Charitable Registration Number: 11896 5516 RR0001



WHAT is Huntington disease?

Huntington disease is an inherited brain disorder which is genetic in nature. Approximately one in every 5,500 Canadians are at-risk of developing the disease. It is like experiencing the symptoms of ALS, Parkinson's and Alzheimer's simultaneously.

Now that you know a little, KNOW MORE.

WHO is the Huntington Society of Canada?

The Huntington Society of Canada (HSC) is a not-for-profit charitable organization which raises funds to deliver individual and group counselling services to support individuals and families living with Huntington disease (HD) and to fund medical research to delay or stop the progression of the disease. The Society also educates health and social services professionals to enable them to better serve people living with HD.

HSC strives to:

- Maximize the quality of life of people living with HD by delivering services
- Further research to slow and to prevent HD
- Enable others to understand the disease

Huntington disease
is devastating



WHO does HD affect?

Huntington disease is a genetic disorder. The HD gene is dominant, which means that each child of a parent with HD has a 50% chance of inheriting the disease and is said to be "at-risk". Males and females have the same risk of inheriting the disease and HD occurs in all races. Primarily, HD affects adults. Symptoms usually appear between the ages of 30 and 45, but the disease can first appear in children as young as 5, or in adults in their 70s.

Huntington disease
is tragic



But there is HOPE

Incredible research is being funded by HSC to find a meaningful treatment for Huntington disease.

2012 Dr. Simonetta Sipione (University of Alberta) and Dr. Ray Truant (McMaster University) successfully reversed HD symptoms in a mouse using a drug called GM1.

2013 Dr. Truant discovered that the protein that causes HD folds into a different shape than the protein from a normal gene.

2014 After a lot of experimenting, Ionis Pharmaceuticals, Inc. (formerly known as Isis) developed a plan to deliver ASOs directly into the fluid that bathes the brain, the cerebrospinal fluid (or CSF).

2015 The first human trials began, testing a "huntingtin lowering" drug designed to attack HD at its root cause.

2016 The "huntingtin lowering" gene silencing drug is granted FDA Orphan Drug Designation. Ionis-HTT RX is in a clinical trial in Europe and Canada.

To donate, visit
cureHD.ca